Table 1: Clinicopathological characteristics of the 74 patients with OSCC and their association with EMMPRIN and Ki-67 expressions.

Factor (%)EMMPRIN overexpressionKi-67 high expression
(%) value (%) value

All cases74 (100%)56 (75.7%)    38 (51.4%)    
Gender                
 Female 19 (25.7%)11 (63.2%)0.1408 (42.1%)0.350
 Male55 (74.3%)44 (80%)30 (54.5%)
Age                
 <62 years37 (50%)30 (81.1%)0.27822 (59.5%)0.163
 ≥62 years37 (50%)26 (70.3%)16 (43.2%)
Location               
 Labial mucosa7 (9.5%)6 (85.7%)0.4301 (14.3%)0.396
 Floor of the mouth10 (13.5%)7 (70%)8 (80%)
 Tongue24 (32.4%)15 (62.5%)13 (54.2%)
 Buccal mucosa 5 (6.8%)5 (100%)2 (40%)
 Retromolar trigone11 (14.9%)8 (72.7%)5 (45.5%)
 Hard palate9 (12.2%)8 (88.9%)3 (55.6%)
 Gingiva8 (10.8%)7 (87.5%)4 (50%)
Tumor size                    
 T113 (17.6%)8 (61.5%)0.1326 (46.2%)0.396
 T229 (39.2%)20 (69%)12 (41.4%)
 T39 (12.2%)9 (100%)6 (66.7%)
 T423 (31%)19 (82.6%)14 (60.9%)
N status                
 N041 (55.4%)28 (68.3%)0.34916 (39%)0.052
 N112 (16.2%)11 (91.7%)7 (58.3%)
 N217 (23%)14 (82.4%)11 (64.7%)
 N34 (5.4%)3 (75%)4 (100%)
Stage                    
 I12 (16.2%)8 (66.7%)0.0646 (50%)0.080
 II23 (31.1%)14 (60.9%)7 (30.4%)
 III10 (13.5%)10 (100%)7 (70%)
 IV29 (39.2%)24 (82.8%)18 (62.1%)
Treatment modality                   
 SG28 (37.8%)20 (71.4%)0.63312 (42.9%)0.522
 SG + RT23 (31.3%)17 (73.9%)13 (56.5%)
 CT + SG or RCT23 (31.3%)19 (82.6%)13 (56.5%)
Tumor grade               
 G142 (56.8%)26 (61.9%)0.00216 (38.1%)0.009
 G2 + G332 (43.2%)30 (93.8%)22 (68.8%)
Margin status*               
 Free of tumor33 (57.9%)23 (69.7%)0.42314 (42.4%)0.236
 With tumor24 (42.1%)19 (79.2%)14 (58.3%)
Perineural permeation               
 Absent66 (89.2%)50 (75.8%)0.96233 (50%)0.504
 Present8 (10.8%)6 (75%)5 (62.5%)
Lymphatic invasion               
 Absent58 (78.4%)46 (79.3%)0.16530 (51.7%)0.903
 Present16 (21.6%)10 (62.5%)8 (50%)

SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
Not determined in the 17 cases.